Isis Pharmaceuticals and Eyetech Pharmaceuticals, Jefferson Medical College and the Kimmel Cancer Center, and Molecula | GenomeWeb

Isis Receives Macugen-Related Milestone Payment from Eyetech

Isis Pharmaceuticals said this week that it has received a $1 million milestone payment from Eyetech Pharmaceuticals in connection with Eyetech’s filing of a new drug application with US regulators for the age-related macular degeneration treatment Macugen.

Although Macugen is not an antisense agent, Eyetech licensed certain patents from Isis needed to develop, manufacture, and commercialize the drug, according to Isis.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: gene flow between ancient chimpanzees and bonobos, and more.

A startup wants to match customers to wine based on their DNA and one critic calls the idea 'silly,' Stat News reports.

Researchers trace the origins of brown rats using genetic analysis to China, the New York Times reports.

In Nature this week: genetic history of HIV in the US, and more.